Sobi publishes Q3 2023 report: Strong revenue and solid performance

Outlook 2023 - unchanged Outlook 2023 - unchanged "We are very pleased with Sobi's development during the quarter. Revenues increased for Haematology and Immunology89 per cent of this was driven by our launch medicines, primarily in the US and internationally. This includes a strong contribution from Vonjo, added through our recent acquisition of CTI BioPharma," said Guido Oelkers, President & CEO. Investors, analysts, and media are invited to participate in a conference call...

Outlook 2023 - unchanged

"We are very pleased with Sobi's development during the quarter. Revenues increased for Haematology and Immunology 89 per cent of this was driven by our launch medicines, primarily in the US and internationally. This includes a strong contribution from Vonjo, added through our recent acquisition of CTI BioPharma," said Guido Oelkers, President & CEO.

Investors, analysts, and media are invited to participate in a conference call which will include a presentation of the results and a Q&A session on 30^th October at 13:00 pm CET, 12:00 pm GMT, and 8:00 am EDT.

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.

To participate in the conference call, please use the following dial-in details:

Sweden: +46 8 5051 0031
United Kingdom: +44 207 107 06 13
United States: +1 631 570 56 13

For other countries, please get details here

Sobi

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2022, revenue amounted to SEK 18.8 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, on 30 October 2023 at 08:00 CEST.

Tobias Cottmann
Acting Head of Communications and Investor Relations

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/sobi-publishes-q3-2023-report-strong-revenue-and-solid-performance-301971141.html